NASDAQ:NURO - Neurometrix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.37 +0.01 (+0.74 %)
(As of 05/24/2018 04:01 AM ET)
Previous Close$1.37
Today's Range$1.36 - $1.39
52-Week Range$1.20 - $4.40
Volume18,439 shs
Average Volume64,089 shs
Market Capitalization$10.23 million
P/E RatioN/A
Dividend YieldN/A
Beta0.27

About Neurometrix (NASDAQ:NURO)

Neurometrix logoNeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Asia, the Middle East, Mexico, and internationally. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.

Receive NURO News and Ratings via Email

Sign-up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NURO
CUSIPN/A
Phone781-890-9989

Debt

Debt-to-Equity RatioN/A
Current Ratio2.53
Quick Ratio2.08

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$17.09 million
Price / Sales0.59
Cash FlowN/A
Price / CashN/A
Book Value$0.93 per share
Price / Book1.47

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-12,850,000.00
Net Margins-47.75%
Return on Equity-161.28%
Return on Assets-89.85%

Miscellaneous

Employees41
Outstanding Shares7,360,000

Neurometrix (NASDAQ:NURO) Frequently Asked Questions

What is Neurometrix's stock symbol?

Neurometrix trades on the NASDAQ under the ticker symbol "NURO."

When did Neurometrix's stock split? How did Neurometrix's stock split work?

Neurometrix's stock reverse split on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2017. An investor that had 100 shares of Neurometrix stock prior to the reverse split would have 13 shares after the split.

How were Neurometrix's earnings last quarter?

Neurometrix (NASDAQ:NURO) posted its earnings results on Thursday, July, 21st. The medical device company reported ($42.96) earnings per share for the quarter, missing the consensus estimate of ($7.44) by $35.52. The medical device company earned $2.65 million during the quarter, compared to analyst estimates of $1.22 million. Neurometrix had a negative return on equity of 161.28% and a negative net margin of 47.75%. View Neurometrix's Earnings History.

What price target have analysts set for NURO?

1 equities research analysts have issued 12 month price objectives for Neurometrix's shares. Their forecasts range from $3.00 to $3.00. On average, they expect Neurometrix's share price to reach $3.00 in the next year. View Analyst Ratings for Neurometrix.

Who are some of Neurometrix's key competitors?

Who are Neurometrix's key executives?

Neurometrix's management team includes the folowing people:
  • Dr. Shai N. Gozani, Founder, Chairman, CEO, Pres & Sec. (Age 53)
  • Mr. Thomas T. Higgins, Sr. VP, CFO, Treasurer & Principal Accounting Officer (Age 66)
  • Mr. Francis X. McGillin, Sr. VP & Chief Commercial Officer (Age 57)
  • Mr. Richard J. Thomas, Pres
  • Mr. Michael J. MacDonald, Sr. VP & GM of Diagnostics

Has Neurometrix been receiving favorable news coverage?

News stories about NURO stock have trended somewhat positive on Thursday, Accern reports. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neurometrix earned a media sentiment score of 0.13 on Accern's scale. They also gave media coverage about the medical device company an impact score of 47.20 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Neurometrix's major shareholders?

Neurometrix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (9.65%) and Thompson Davis & CO. Inc. (1.23%). Company insiders that own Neurometrix stock include Francis X Mcgillin, Shai Gozani and Thomas T Higgins. View Institutional Ownership Trends for Neurometrix.

Which major investors are buying Neurometrix stock?

NURO stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC and Thompson Davis & CO. Inc.. Company insiders that have bought Neurometrix stock in the last two years include Francis X Mcgillin, Shai Gozani and Thomas T Higgins. View Insider Buying and Selling for Neurometrix.

How do I buy shares of Neurometrix?

Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurometrix's stock price today?

One share of NURO stock can currently be purchased for approximately $1.37.

How big of a company is Neurometrix?

Neurometrix has a market capitalization of $10.23 million and generates $17.09 million in revenue each year. Neurometrix employs 41 workers across the globe.

How can I contact Neurometrix?

Neurometrix's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The medical device company can be reached via phone at 781-890-9989 or via email at [email protected]


MarketBeat Community Rating for Neurometrix (NURO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  128 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  238
MarketBeat's community ratings are surveys of what our community members think about Neurometrix and other stocks. Vote "Outperform" if you believe NURO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NURO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Neurometrix (NASDAQ:NURO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Neurometrix in the last 12 months. Their average twelve-month price target is $3.00, suggesting that the stock has a possible upside of 118.98%. The high price target for NURO is $3.00 and the low price target for NURO is $3.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.00$3.00$3.00$3.00
Price Target Upside: 118.98% upside74.42% upside74.42% upside74.42% upside

Neurometrix (NASDAQ:NURO) Consensus Price Target History

Price Target History for Neurometrix (NASDAQ:NURO)

Neurometrix (NASDAQ:NURO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/20/2017HC WainwrightReiterated RatingBuy$10.00 ➝ $3.00N/AView Rating Details
10/21/2016Rodman & RenshawReiterated RatingBuy$36.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Neurometrix (NASDAQ:NURO) Earnings History and Estimates Chart

Earnings by Quarter for Neurometrix (NASDAQ:NURO)

Neurometrix (NASDAQ NURO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/20/2017Q3 2017($1.60)($3.11)$3.55 millionViewN/AView Earnings Details
7/20/2017Q2 2017($2.83)($2.49)$4.40 million$4.31 millionViewN/AView Earnings Details
4/20/2017Q1 2017($3.92)($7.28)$4.17 million$4.31 millionViewN/AView Earnings Details
1/26/2017Q416($6.00)($4.16)$3.48 million$3.70 millionViewListenView Earnings Details
10/20/2016Q316($6.56)($6.08)$3.01 million$3.39 millionViewListenView Earnings Details
7/21/2016Q216($7.44)($42.96)$1.22 million$2.65 millionViewListenView Earnings Details
4/21/2016Q116($7.60)($8.00)$2.65 million$2.28 millionViewListenView Earnings Details
2/12/2016Q4 2015($25.52)$2.74 millionViewN/AView Earnings Details
10/22/2015Q315($0.64)($2.08)$6.47 million$2.10 millionViewListenView Earnings Details
7/22/2015Q215($3.84)$9.80 million$1.22 millionViewListenView Earnings Details
4/21/2015Q1 2015($12.48)$1.28 millionViewN/AView Earnings Details
2/12/2015Q414($2.88)$4.62 million$1.41 millionViewN/AView Earnings Details
10/28/2014Q3 2014($8.32)$1.43 millionViewN/AView Earnings Details
7/24/2014Q413($6.80)$1.16 million$1.34 millionViewN/AView Earnings Details
4/24/2014Q1 2014($9.60)$1.33 millionViewN/AView Earnings Details
2/13/2014($6.96)$1.40 millionViewListenView Earnings Details
10/23/2013Q313($2.08)$1.77 million$1.31 millionViewListenView Earnings Details
7/25/2013Q2 2013($7.36)$2.20 million$1.20 millionViewN/AView Earnings Details
4/25/2013Q1 2013($33.92)$1.40 millionViewN/AView Earnings Details
2/19/2013Q4 2012($40.31)($170.85)ViewN/AView Earnings Details
10/25/2012Q3 2012($40.31)($40.31)ViewN/AView Earnings Details
7/26/2012Q2 2012($40.31)($42.23)ViewN/AView Earnings Details
4/24/2012Q1 2012($101.74)($63.35)ViewN/AView Earnings Details
2/15/2012Q4 2011($143.97)($120.94)ViewN/AView Earnings Details
10/27/2011Q3 2011($161.25)($120.94)ViewN/AView Earnings Details
7/28/2011Q2 2011($149.70)($126.67)ViewN/AView Earnings Details
4/28/2011Q1 2011($138.18)ViewN/AView Earnings Details
2/3/2011($1.36)($1.44)ViewN/AView Earnings Details
11/9/2010Q3 2010($195.76)($172.73)ViewN/AView Earnings Details
8/10/2010Q2 2010($230.31)($230.31)ViewN/AView Earnings Details
5/11/2010Q1 2010($195.76)($230.31)ViewN/AView Earnings Details
2/10/2010Q4 2009($92.12)($92.12)ViewN/AView Earnings Details
11/5/2009Q3 2009($241.82)($132.43)ViewN/AView Earnings Details
8/5/2009Q2 2009($149.70)($148.55)ViewN/AView Earnings Details
5/6/2009Q1 2009($126.67)($100.18)ViewN/AView Earnings Details
2/10/2009Q4 2008($218.79)($84.06)ViewN/AView Earnings Details
11/4/2008Q3 2008($264.85)($238.37)ViewN/AView Earnings Details
8/5/2008Q2 2008($299.40)($297.10)ViewN/AView Earnings Details
5/6/2008Q1 2008($241.82)($365.04)ViewN/AView Earnings Details
2/12/2008Q4 2007($276.37)($194.61)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Neurometrix (NASDAQ:NURO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Neurometrix (NASDAQ NURO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.50%
Institutional Ownership Percentage: 14.67%
Insider Trading History for Neurometrix (NASDAQ:NURO)
Insider Trading History for Neurometrix (NASDAQ:NURO)

Neurometrix (NASDAQ NURO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2018Thomas T HigginsInsiderBuy1,000$1.33$1,330.0077,196View SEC Filing  
2/23/2018Shai GozaniCEOBuy1,500$1.54$2,310.0076,196View SEC Filing  
2/20/2018Shai GozaniCEOBuy1,000$1.36$1,360.0073,696View SEC Filing  
2/20/2018Thomas T HigginsInsiderBuy1,500$1.36$2,040.00View SEC Filing  
2/12/2018Francis X McgillinSVPBuy3,849$1.30$5,003.708,584View SEC Filing  
2/12/2018Thomas T HigginsInsiderBuy1,500$1.34$2,010.0029,963View SEC Filing  
2/9/2018Shai GozaniCEOBuy5,000$1.28$6,400.0071,196View SEC Filing  
2/6/2018Thomas T HigginsCFOBuy1,000$1.45$1,450.0028,463View SEC Filing  
2/5/2018Shai GozaniCEOBuy5,000$1.48$7,400.0066,196View SEC Filing  
2/1/2018Thomas T HigginsInsiderBuy2,500$1.55$3,875.0027,463View SEC Filing  
1/31/2018Shai GozaniCEOBuy2,000$1.69$3,380.0059,196View SEC Filing  
1/29/2018Shai GozaniCEOBuy1,000$1.75$1,750.0057,196View SEC Filing  
12/13/2017Shai GozaniCEOBuy3,000$1.78$5,340.0056,196View SEC Filing  
12/11/2017Shai GozaniCEOBuy2,000$1.70$3,400.0051,196View SEC Filing  
12/7/2017Shai GozaniCEOBuy6,333$1.50$9,499.5046,196View SEC Filing  
12/7/2017Thomas T HigginsCFOBuy2,000$1.51$3,020.0022,963View SEC Filing  
12/1/2017Shai GozaniCEOBuy3,000$1.70$5,100.00View SEC Filing  
11/16/2017Shai GozaniCEOBuy2,000$1.94$3,880.0036,863View SEC Filing  
10/25/2017Shai GozaniCEOBuy5,000$1.67$8,350.0034,863View SEC Filing  
10/25/2017Thomas T HigginsInsiderBuy2,500$1.70$4,250.0020,963View SEC Filing  
10/23/2017Thomas T HigginsInsiderBuy2,500$1.77$4,425.0018,463View SEC Filing  
6/21/2017Thomas T HigginsInsiderBuy1,000$2.83$2,830.0015,963View SEC Filing  
6/16/2017Shai GozaniCEOBuy3,500$2.90$10,150.0027,363View SEC Filing  
6/15/2017Thomas T HigginsInsiderBuy3,500$2.98$10,430.0014,963View SEC Filing  
6/14/2017Shai GozaniCEOBuy5,000$2.97$14,850.0023,863View SEC Filing  
6/14/2017Thomas T HigginsInsiderBuy2,300$2.97$6,831.0011,463View SEC Filing  
11/1/2016Shai GozaniCEOBuy3,000$1.31$3,930.00150,909View SEC Filing  
10/28/2016Thomas T HigginsInsiderBuy3,000$1.32$3,960.0073,309View SEC Filing  
10/27/2016Shai GozaniCEOBuy6,000$1.32$7,920.00147,909View SEC Filing  
8/31/2016Thomas T HigginsCFOBuy1,400$1.41$1,974.0070,309View SEC Filing  
8/18/2016Shai GozaniCEOBuy5,000$1.49$7,450.00141,909View SEC Filing  
8/12/2016Thomas T HigginsInsiderBuy2,000$1.45$2,900.0068,909View SEC Filing  
6/1/2016Shai GozaniCEOBuy2,500$1.71$4,275.00139,409View SEC Filing  
5/23/2016Francis X McgillinVPBuy1,000$1.65$1,650.0037,886View SEC Filing  
5/19/2016Shai GozaniCEOBuy12,000$1.55$18,600.00132,409View SEC Filing  
5/19/2016Thomas T HigginsCFOBuy3,200$1.54$4,928.0064,909View SEC Filing  
8/28/2015Thomas T HigginsCFOBuy4,500$0.92$4,140.0085,494View SEC Filing  
8/20/2015Thomas T HigginsCFOBuy5,500$0.91$5,005.0080,994View SEC Filing  
8/11/2015Shai GozaniCEOBuy16,300$0.91$14,833.00View SEC Filing  
11/9/2012Shai GozaniCEOBuy26,800$0.55$14,740.00View SEC Filing  
8/27/2012Krishnamurthy BalachandranCOOBuy5,000$0.67$3,350.00View SEC Filing  
8/21/2012Thomas T HigginsCFOBuy5,000$0.64$3,200.00View SEC Filing  
8/13/2012Krishnamurthy BalachandranCOOBuy5,000$0.70$3,500.00View SEC Filing  
8/8/2012Thomas T HigginsCFOBuy5,000$0.70$3,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Neurometrix (NASDAQ NURO) News Headlines

Source:
DateHeadline
Zacks: Neurometrix (NURO) Receives Average Rating of "Hold" from BrokeragesZacks: Neurometrix (NURO) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 21 at 1:41 PM
 Neurometrix (NURO) Receives Consensus Recommendation of "Hold" from Analysts Neurometrix (NURO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 5 at 1:41 PM
Preliminary Results from Quell Chronic Low Back Pain Study to be Presented at World Institute of Pain World CongressPreliminary Results from Quell Chronic Low Back Pain Study to be Presented at World Institute of Pain World Congress
finance.yahoo.com - May 3 at 5:02 PM
NeuroMetrix, Inc. to Participate in Upcoming Disruptive Growth & Healthcare Conference in New York CityNeuroMetrix, Inc. to Participate in Upcoming Disruptive Growth & Healthcare Conference in New York City
feeds.benzinga.com - May 1 at 11:53 AM
Head to Head Analysis: Neurometrix (NURO) versus Irhythm Technologies (IRTC)Head to Head Analysis: Neurometrix (NURO) versus Irhythm Technologies (IRTC)
www.americanbankingnews.com - April 21 at 9:50 AM
NeuroMetrix, Inc. to Host Earnings CallNeuroMetrix, Inc. to Host Earnings Call
finance.yahoo.com - April 19 at 8:42 AM
NeuroMetrix Reports Q1 2018 Financial ResultsNeuroMetrix Reports Q1 2018 Financial Results
finance.yahoo.com - April 19 at 8:42 AM
NeuroMetrix to Present Data on Quell Sleep Monitoring Technology at Upcoming American Academy of Neurology Annual MeetingNeuroMetrix to Present Data on Quell Sleep Monitoring Technology at Upcoming American Academy of Neurology Annual Meeting
finance.yahoo.com - April 18 at 5:22 PM
Neurometrix (NURO) Downgraded by ValuEngineNeurometrix (NURO) Downgraded by ValuEngine
www.americanbankingnews.com - April 18 at 1:24 PM
Neurometrix (NURO) Cut to "Hold" at Zacks Investment ResearchNeurometrix (NURO) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 9:15 PM
Neurometrix (NURO) Scheduled to Post Quarterly Earnings on ThursdayNeurometrix (NURO) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - April 15 at 8:15 PM
Financial Contrast: Neurometrix (NURO) & Restoration Robotics (HAIR)Financial Contrast: Neurometrix (NURO) & Restoration Robotics (HAIR)
www.americanbankingnews.com - April 13 at 11:35 PM
NeuroMetrix, Inc. Announces Date for 2018 First Quarter Financial Results Conference CallNeuroMetrix, Inc. Announces Date for 2018 First Quarter Financial Results Conference Call
feeds.benzinga.com - April 11 at 11:16 AM
NeuroMetrix (NURO) Reports Results of Large Clinical Study of Quell Wearable Pain ReliefNeuroMetrix (NURO) Reports Results of Large Clinical Study of Quell Wearable Pain Relief
www.streetinsider.com - April 10 at 5:09 PM
NeuroMetrix Reports Results of Large Clinical Study of Quell Wearable Pain ReliefNeuroMetrix Reports Results of Large Clinical Study of Quell Wearable Pain Relief
finance.yahoo.com - April 10 at 5:09 PM
 Neurometrix Inc (NURO) Given Average Recommendation of "Hold" by Analysts Neurometrix Inc (NURO) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 4 at 11:12 PM
Neurometrix (NURO) Upgraded at Zacks Investment ResearchNeurometrix (NURO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 26 at 1:58 PM
Free Research Reports on These Medical Supplies Stocks -- Hill-Rom, NeuroMetrix, Akers Biosciences, and Antares PharmaFree Research Reports on These Medical Supplies Stocks -- Hill-Rom, NeuroMetrix, Akers Biosciences, and Antares Pharma
www.bizjournals.com - March 21 at 9:36 AM
Should You Buy NeuroMetrix Inc (NASDAQ:NURO) Now?Should You Buy NeuroMetrix Inc (NASDAQ:NURO) Now?
finance.yahoo.com - March 8 at 6:10 PM
NeuroMetrix to Present Quell Data at 2018 American Pain Society MeetingNeuroMetrix to Present Quell Data at 2018 American Pain Society Meeting
finance.yahoo.com - March 1 at 5:30 PM
Contrasting SurModics (SRDX) and Neurometrix (NURO)Contrasting SurModics (SRDX) and Neurometrix (NURO)
www.americanbankingnews.com - February 26 at 1:34 AM
Comparing Neurometrix (NURO) & Palomar Medical Technologies (PMTI)Comparing Neurometrix (NURO) & Palomar Medical Technologies (PMTI)
www.americanbankingnews.com - February 12 at 5:12 PM
NeuroMetrix Inc (NURO) Files 10-K for the Fiscal Year Ended on December 31, 2017NeuroMetrix Inc (NURO) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 8 at 3:57 PM
Neurometrix (NURO) Lifted to Sell at ValuEngineNeurometrix (NURO) Lifted to Sell at ValuEngine
www.americanbankingnews.com - February 4 at 7:40 PM
BRIEF-Neurometrix Inc Says Net Loss Was About $2.9 Mln In Q4 2017 Compared To $2.8 Mln In Q4 2016BRIEF-Neurometrix Inc Says Net Loss Was About $2.9 Mln In Q4 2017 Compared To $2.8 Mln In Q4 2016
www.reuters.com - January 25 at 3:59 PM
NeuroMetrix Q4 Reports Wider Net Loss, Despite Revenue GrowthNeuroMetrix Q4 Reports Wider Net Loss, Despite Revenue Growth
www.nasdaq.com - January 25 at 3:59 PM
NeuroMetrix Reports Q4 and Full Year 2017 Financial ResultsNeuroMetrix Reports Q4 and Full Year 2017 Financial Results
finance.yahoo.com - January 25 at 9:39 AM
Zacks Investment Research Downgrades Neurometrix (NURO) to SellZacks Investment Research Downgrades Neurometrix (NURO) to Sell
www.americanbankingnews.com - January 24 at 9:42 AM
Symmetry Medical (SMA) versus Neurometrix (NURO) Financial ReviewSymmetry Medical (SMA) versus Neurometrix (NURO) Financial Review
www.americanbankingnews.com - January 23 at 9:28 PM
Intersect ENT (XENT) vs. Neurometrix (NURO) Head to Head AnalysisIntersect ENT (XENT) vs. Neurometrix (NURO) Head to Head Analysis
www.americanbankingnews.com - January 23 at 1:18 AM
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2017 Financial Results Conference CallNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2017 Financial Results Conference Call
finance.yahoo.com - January 18 at 4:12 PM
Here’s Why Neurometrix Inc Rose as Much as 60% TodayHere’s Why Neurometrix Inc Rose as Much as 60% Today
finance.yahoo.com - January 17 at 4:43 PM
NeuroMetrix Reports Preliminary 2017 Financial HighlightsNeuroMetrix Reports Preliminary 2017 Financial Highlights
finance.yahoo.com - January 8 at 10:23 AM
NeuroMetrix to Present at Upcoming Biotech Showcase and Digital Medicine Showcase ConferencesNeuroMetrix to Present at Upcoming Biotech Showcase and Digital Medicine Showcase Conferences
feeds.benzinga.com - January 3 at 12:26 PM
ValuEngine Upgrades Neurometrix (NURO) to SellValuEngine Upgrades Neurometrix (NURO) to Sell
www.americanbankingnews.com - December 29 at 10:10 PM
Head-To-Head Review: NeuroMetrix (NURO) & Orthofix International (OFIX)Head-To-Head Review: NeuroMetrix (NURO) & Orthofix International (OFIX)
www.americanbankingnews.com - December 13 at 9:38 PM
Globus Medical (GMED) & NeuroMetrix (NURO) Financial SurveyGlobus Medical (GMED) & NeuroMetrix (NURO) Financial Survey
www.americanbankingnews.com - December 13 at 1:34 PM
NeuroMetrix (NURO) Announces New U.S. Patent for Quell Wearable TechnologyNeuroMetrix (NURO) Announces New U.S. Patent for Quell Wearable Technology
www.streetinsider.com - November 30 at 10:52 AM
NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable TechnologyNeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology
finance.yahoo.com - November 29 at 10:19 AM
Contrasting NeuroMetrix (NURO) & Bio-Rad Laboratories (BIO)Contrasting NeuroMetrix (NURO) & Bio-Rad Laboratories (BIO)
www.americanbankingnews.com - November 19 at 1:08 AM
Interested In The Healthcare Industry? Take A Look At NeuroMetrix Inc (NURO)Interested In The Healthcare Industry? Take A Look At NeuroMetrix Inc (NURO)
finance.yahoo.com - November 18 at 9:04 AM
Comparing NeuroMetrix (NURO) and LDR Holding Corp (LDRH)Comparing NeuroMetrix (NURO) and LDR Holding Corp (LDRH)
www.americanbankingnews.com - November 15 at 11:24 PM
What Is NeuroMetrix Inc’s (NURO) Share Price Doing?What Is NeuroMetrix Inc’s (NURO) Share Price Doing?
finance.yahoo.com - November 2 at 7:06 AM
NeuroMetrix Closes $3.5 Million Equity OfferingNeuroMetrix Closes $3.5 Million Equity Offering
finance.yahoo.com - November 1 at 7:05 AM
-$1.60 EPS Expected for NeuroMetrix, Inc. (NURO) This Quarter-$1.60 EPS Expected for NeuroMetrix, Inc. (NURO) This Quarter
www.americanbankingnews.com - October 27 at 5:30 AM
NeuroMetrix (NURO) vs. Integra LifeSciences Holdings Corporation (IART) Head-To-Head SurveyNeuroMetrix (NURO) vs. Integra LifeSciences Holdings Corporation (IART) Head-To-Head Survey
www.americanbankingnews.com - October 26 at 7:58 AM
NeuroMetrix, Inc. :NURO-US: Earnings Analysis: Q3, 2017 By the Numbers : October 24, 2017NeuroMetrix, Inc. :NURO-US: Earnings Analysis: Q3, 2017 By the Numbers : October 24, 2017
finance.yahoo.com - October 25 at 8:24 AM
Comparing K2M Group Holdings (KTWO) & NeuroMetrix (NURO)Comparing K2M Group Holdings (KTWO) & NeuroMetrix (NURO)
www.americanbankingnews.com - October 22 at 6:22 AM
NeuroMetrix, Inc. (NURO) Given Buy Rating at HC WainwrightNeuroMetrix, Inc. (NURO) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - October 21 at 2:22 PM
NeuroMetrix Reports Q3 2017 Financial ResultsNeuroMetrix Reports Q3 2017 Financial Results
finance.yahoo.com - October 20 at 6:58 AM

SEC Filings

Neurometrix (NASDAQ:NURO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Neurometrix (NASDAQ:NURO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Neurometrix (NASDAQ NURO) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.